Global X Robotics and Artificial Intelligence ETF vs Canopy Growth Corp — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $38, while Canopy Growth Corp trades at $1 (market cap $421.10M). The key difference: Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| BOTZ | CGC | |
|---|---|---|
52-Week High | $41.63 | $1.92 |
52-Week Low | $31.99 | $0.86 |
Market Cap | — | $421.10M |
Sector | — | Health |
Enterprise Value | — | $378.55M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CGC trades at $0.95, down 1.86% in the last session, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year, beating estimates, but continues to post net losses. Recent news highlights expansion in European cannabis markets and cost-cutting efforts, while the stock remains volatile amid regulatory uncertainty.
Outlook is cautious due to persistent losses and high debt, though improving cash flow and revenue growth offer potential upside. Key risks include regulatory delays in U.S. cannabis rescheduling and competitive pressures. Investors should weigh the speculative nature against any positive regulatory catalysts.
Trailing returns across standard periods
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →